Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) just unveiled an announcement.
Hikma Pharmaceuticals has continued execution of its recently announced $250 million share repurchase programme, buying 192,500 ordinary shares on 27 February 2026 through Citigroup Global Markets at a volume-weighted average price of 1,346.66 pence. The company intends to cancel these shares, and following this tranche it has acquired a total of 280,000 shares for £3.8 million, leaving 221,606,453 voting shares in issue and modestly enhancing earnings per share and capital return for investors.
The transaction increases the number of shares held in treasury to 12,833,233, while confirming Hikma’s commitment to returning surplus capital to shareholders alongside its core pharmaceuticals operations. By shrinking the free float and reinforcing capital discipline through the buyback, Hikma may support its share price and signal confidence in its financial position, a move likely to be closely watched by equity investors and analysts covering the generics and injectables sector.
The most recent analyst rating on (GB:HIK) stock is a Sell with a £13.50 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational generics and specialty pharmaceuticals company listed in London and on Nasdaq Dubai. It focuses on developing, manufacturing and distributing branded and non-branded generic medicines, with a strong presence in injectable and oral formulations across the U.S., MENA and other international markets.
Average Trading Volume: 1,010,435
Technical Sentiment Signal: Sell
Current Market Cap: £3.06B
See more data about HIK stock on TipRanks’ Stock Analysis page.